AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01996449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: The subject will be started on Eplerenone (Inspra) 50-200mg daily, which he or she will continue for a period of 8 weeks. Following the 8-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued
Study NCT01996449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: The subject will be started on Amlodipine (Norvasc) 2.5 -10mg daily, which he or she will continue for a period of 8 weeks. Following the 8-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
Study NCT01996449 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microneurography
Description: Investigators will measure sympathetic nerve activity from the peroneal nerve by inserting a tiny needle directly into the nerve in the leg. Investigators will localize the nerve by electrical stimulation over the skin using a blunt probe. With this stimulation, subject will notice either involuntary twitching or a tingling sensation, which may be annoying but not painful. Investigators will then introduce a tiny, sterile wire needle (an electrode) through the skin at the same location. When the tip of the needle enters the nerve, subjects may again notice involuntary muscle twitches or tingling in the leg. Investigators will then turn the electrical stimulator off and make minor adjustments in the position of the needle until investigators begin to record the nerve signals. The recording needle will remain in position throughout the study.
Study NCT01996449 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rhythmic handgrip exercise
Description: Subjects will perform a rhythmic handgrip exercise at 30% or 45% of maximal voluntary contraction for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this handgrip exercise
Study NCT01996449 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sustained hand grip
Description: Subjects will perform a sustained handgrip exercise at 30% of maximal voluntary contraction for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this handgrip exercise.
Study NCT01996449 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forearm blood flow
Description: Using high-resolution ultrasound, investigators will measure skeletal muscle blood flow in the forearm at rest, following sustained handgrip exercise
Study NCT01996449 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arm cycling exercise
Description: Subjects will perform a cycling arm exercise with a stationary cycling device. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this exercise.
Study NCT01996449 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cold Pressor test
Description: Subjects will place hand in cold water with ice for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline, during and 2 minutes after the test.
Study NCT01600690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Statin withdrawal
Description: Patients are instructed to stop taking statin pills for the duration of the study. The rest of therapy will remain unchanged.
Study NCT00511095 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HEPLISAV
Description: Intramuscular (IM) injections 0.5mL on Day 0 and Week 4
Study NCT00804986 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 of 5 volumes of placebo given once weekly for 12 weeks as a subcutaneous injection.
Study NCT02756546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Study NCT02756546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Study NCT02756546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Study NCT00467012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 10mg/kg，Day1, 15 of 1 cycle(4 weeks)
Study NCT00467012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 90mg/ m2，Day1, 8, 15 of 1 cycle(4 weeks)
Study NCT00278551 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune ablation and hematopoietic stem cell transplant
Description: Autologous Hematopoietic Stem Cell Transplant
Study NCT02347254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial ExAblate
Description: Transcranial ExAblate MRgFUS
Study NCT00509938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human lactoferrin peptide 1-11
Description: Each subject will receive a single intravenous dose of hLF1-11 given in a volume of 20mL given over 20 minutes i.e. 1mL/per minute.
Study NCT01853852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR181413A/AT1001 solution
Description: Powder for reconstitution
Study NCT01853852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GR181413A/AT1001 solution
Description: Powder for reconstitution
Study NCT03560232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin + Gentamicin
Description: See arm description
Study NCT03560232 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clindamycin + Gentamicin
Description: See arm description
Study NCT01853852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR181413A/AT1001 capsule
Description: Size 2, hard gelatin capsule, white opaque / blue opaque
Study NCT02387645 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lavage of the Uterus
Description: The lavage will be performed in the operating theatre under general anesthesia. The ALPINE technique includes the following steps. A three way catheter (catheter for uterine and tubal lavage) is inserted into the cervical canal and a balloon is inflated to seal the cervical canal. The patient is put into anti-Trendellenburg positioning. Normal saline is slowly flushed into the uterine cavity and proximal tubes. After the lavage is finished, the balloon is deflated and the catheter is removed. A cap is put on the collection syringe and the syringe is sent to the laboratory.
Study NCT03152071 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robot assited thoracic surgery
Description: The lobectomy will be preformed in case of an operable lung cancer. The thoracic surgery technique used is robot assisted thoracic surgery
Study NCT03152071 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video assited thoracic surgery
Description: The lobectomy will be preformed in case of an operable lung cancer. The thoracic surgery technique used is video assisted thoracic surgery.
Study NCT04397783 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: construction of an end colostomy
Description: longitudinal incision in the construction of an end colostomy
Study NCT00674245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: 40 mg once daily for 4 weeks
Study NCT00674245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: 40 mg once daily improves sleep quality in patients with GERD.
Study NCT00674245 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 40 mg once daily for 4 weeks
Study NCT01690572 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel coated balloon catheter
Description: Dilatation of the target lesion
Study NCT03101683 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Partial chest wall radiation therapy
Description: A dose of 40 Gy in 16 fractions (2.5 Gy per fraction) is delivered in the area at risk of local recurrence (skin and the pectoralis muscles) delineated by surgical clips and 3D-MRI reconstruction for a precise localization of the tumor excised
Study NCT04113005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: To evaluate the safety and tolerability of Desmopressin in CRPC subjects starting Docetaxel treatment. Additionally, CTCs will be collected before and after Desmopressin/Docetaxel treatment to evaluate therapeutic efficacy.
Study NCT01690572 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: uncoated balloon catheter sprinter legend
Description: Dilatation of the target lesion
Study NCT02426996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scan of shoulder
Description: A scan (no injection) of the concerned shoulder will be performed at 3 months post-surgery. Cuts in three planes of space, including all of the glenoid. 3D reconstructions.
Study NCT02291094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Patients in intravenous lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
Study NCT02291094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Patients in remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
Study NCT02273999 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: RecoveryRx™
Description: Appliance of the device after surgery
Study NCT02273999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RecoveryRx™
Description: Appliance of the device after surgery
Study NCT02018900 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ecologic 825/scFOS
Study NCT02018900 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01988649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Oxytocin
Description: Administration of intranasal Oxytocin
Study NCT01988649 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: Administration of normal saline intranasally.
Study NCT02926794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SA and II
Description: Self affirmation intervention where participants rank 11 values, then write about why their top ranked value is important AND Implementation intentions intervention where participants form two implementation intentions (If/then) statements regarding drinking behavior and write why these are important
Study NCT02926794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SA and No II
Description: Self affirmation intervention where participants rank 11 values, then write about why their top ranked value is important AND No implementation intentions intervention where participants write why selected health strategies are important (and do nothing else)
Study NCT02926794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No SA and II
Description: Control writing intervention where participants rank 11 values, then write about why their 10th ranked value is important to someone else AND Implementation intentions intervention where participants form two implementation intentions (If/then) statements regarding drinking behavior and write why these are important
Study NCT02926794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No SA and No II
Description: Control writing intervention where participants rank 11 values, then write about why their 10th ranked value is important to someone else AND No implementation intentions intervention where participants write why selected health strategies are important (and do nothing else)
Study NCT00754065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)
Description: Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one encapsulated BAY86-5027 for 28 days per Cycle, for 13 treatment cycles: Days 1-2, 3.0 mg EV; Days 3-7, 2.0 mg EV+2.0 mg DNG; Days 8-24, 2.0 mg EV+3.0 mg DNG; Days 25-26, 1.0 mg EV; Days 27-28, placebo
Study NCT00754065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ortho Tri Cyclen Lo
Description: Dose--Ethinylestradiol (EE) + Norgestimate (NGM) Triphasic 21-day regimen. Daily oral administration of one encapsulated Ortho Tri-Cyclen Lo for 28 days per Cycle, for 13 treatment cycles: Days 1-7, 0.025 mg EE+0.180 NGM; Days 8-14, 0.025 mg EE+0.215 NGM; Days 15-21, 0.025 mg EE+0.250 NGM; Days 27-28, placebo
Study NCT01853852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GR181413A/AT1001 capsule
Description: Size 2, hard gelatin capsule, white opaque / blue opaque
Study NCT01853852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Potable water
Description: Matched, Size 2, hard gelatin capsule, white opaque/blue opaque
Study NCT01853852 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Potable water
Description: Matched, Size 2, hard gelatin capsule, white opaque/blue opaque
Study NCT01853852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Solution matched
Study NCT01853852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Solution matched
Study NCT03484988 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oil
Description: The participants were asked to take corn oil capsule twice a day, 4 capsules (500mg/capsules) each time. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
Study NCT03484988 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Echium oil
Description: The participants were asked to take echium oil capsule twice a day, 4 capsules (500mg/capsules) each time. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
Study NCT03484988 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed oil
Description: The participants were asked to take mixed oil(echium oil,camelina oil,safflower oil) twice a day, 4 capsules (500mg/capsules) each time. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
Study NCT03971851 — intervention group
Intervention type: OTHER
Intervention: Frailty risk groups
Description: Patients older than 65 will be separated into groups of varying frailty risk
Study NCT02940860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside/ferric derisomaltose
Description: Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride (100 mL bags) and administered as a single IV infusion over approximately 20 minutes.
Study NCT02940860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose
Description: Iron sucrose (Venofer®; 20 mg elemental iron/mL) was the comparator in this trial. Iron sucrose was administered as 200 mg undiluted IV injections over approximately 2-5 minutes and repeated according to standard practice or physician choice up to a maximum of five times within the first two weeks starting at baseline. A cumulative dose of 1000 mg was recommended.
Study NCT04556201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOLTIVE™ Premium SuperPulsed Laser Fiber System
Description: SOLTIVE™ SuperPulsed Laser Fiber System and SOLTIVE™ Laser Fibers for single-use only
Study NCT02910089 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Shared Decision Making
Description: This prospective study will include 700 beneficiaries of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ).
Study NCT02470429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SYSTANE HYDRATION lubricant eye drops
Description: Preserved with POLYQUAD (polidronium chloride) 0.001%
Study NCT02470429 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyabak 0.15% eye drops
Description: Preservative-free
Study NCT02470429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% saline eye drops
Description: Preservative-free, one drop 4 times a day in each eye (run-in period)
Study NCT02470429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% saline eye drops
Description: Preservative-free, one drop 4 times a day in each eye (run-in period)
Study NCT01973972 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight management
Description: Weight management group visits using low-carbohydrate diet followed for weight management.
Study NCT01973972 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shared medical appointments (SMA)
Description: Diabetes management group visits for diabetes management.
Study NCT01973972 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared medical appointments (SMA)
Description: Diabetes management group visits for diabetes management.
Study NCT01438359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21 and Furosemide with food
Description: The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Furosemide will be 40 mg/day
Study NCT01438359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No PA21; Furosemide with food
Description: The maximum dosage of Furosemide will be 40 mg/day
Study NCT01438359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21 with food and Furosemide 2hrs later
Description: The maximum dose of PA21 will be 15 g/day. The maximum dose of Furosemide will be 40 mg/day
Study NCT03582436 — intervention group
Intervention type: PROCEDURE
Intervention: Kidney transplantation
Description: For the patients with the kidney transplantation, these parameters will be analysis:~Transcriptomics analysis Characteristics of anti HLA DSA analysis Non-HLA antibodies analysis Omics blood analysis Urine chemokines analysis
Study NCT03435276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977
Description: Randomized subjects will receive AZD9977 oral suspension at a dose of 50 mg in Cohort 1, 150 mg in Cohort 2 and 300 mg in Cohort 3
Study NCT03435276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Randomized subjects will receive orally AZD9977 matched placebo in Cohorts 1, 2 and 3
Study NCT01782222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Rotigotine, transdermal patches:~10 cm\^2 (2 mg / 24 hours); 20 cm\^2 (4 mg / 24 hours); 30 cm\^2 (6 mg / 24 hours); 40 cm\^2 (8 mg / 24 hours)~The maximum Rotigotine dose allowed is 8 mg / 24 hours or 16 mg / 24 hours for patients with advanced Parkinson's Disease and 6 mg / 24 hours or 8 mg / 24 hours for those with early Parkinson's Disease Duration: up to 21 weeks (including de-escalation)
Study NCT02532413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly IC
Description: Poly IC can induce innate immune responses.It may enhance the antiviral efficacy of Entecavir.
Study NCT02532413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Entecavir can inhibit the replication of HBV.
Study NCT02532413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Entecavir can inhibit the replication of HBV.
Study NCT03135639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NeuroConn Plus Stimulator tACS
Description: Transcranial alternating current stimulation (tACS) is a novel, noninvasive brain stimulation approach in which weak electric currents are applied to the scalp. The electric currents that are applied to the scalp are in a sine-wave pattern.
Study NCT03135639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NeuroConn Plus Stimulator Sham
Description: For sham stimulation, the participant receives up to 1 minute of tACS stimulation until the stimulation fades. This mimics the same skin sensations that a participant would experience during a tACS session.
Study NCT01782222 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, matching transdermal patches~Duration: up to 21 weeks (including de-escalation)
Study NCT03675919 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Scale
Description: self-monitoring of body weight; with automatic data transfer into the personalized and secured online portal
Study NCT03675919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scale
Description: self-monitoring of body weight; with automatic data transfer into the personalized and secured online portal
Study NCT03675919 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Step counter
Description: self-monitoring of physical activity; with automatic data transfer into the personalized and secured online portal
Study NCT03675919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Step counter
Description: self-monitoring of physical activity; with automatic data transfer into the personalized and secured online portal
Study NCT03675919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood glucose meter with test stripes
Description: self-monitoring of blood glucose; with automatic data transfer into the personalized and secured online portal